[{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Texas Health Resources","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Texas Health Resources","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Texas Health Resources"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Assertio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Assertio Therapeutics"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Eli Lilly | Cancer Prevention Research Institute of Texas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UT Southwestern Medical Center \/ Eli Lilly | Cancer Prevention Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Eli Lilly | Cancer Prevention Research Institute of Texas"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BAY2402234","moa":"DHODH","graph1":"Oncology","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Bayer AG"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Celldex Therapeutics | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ Celldex Therapeutics | Gateway for Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Celldex Therapeutics | Gateway for Cancer Research"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Oncology","graph2":"Phase III","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"UT Southwestern Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"Iomab-B","moa":"monoclonal antibodies: tumors; iodine-containing contrast media","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Actinium pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Actinium pharmaceuticals"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Chiesi Group"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Astellas Pharma"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Commonwealth Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"UT Southwestern Medical Center \/ Commonwealth Healthcare Corporation","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Commonwealth Healthcare Corporation"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Arcus Biosciences | Cancer Prevention Research Institute of Texas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Arcus Biosciences | Cancer Prevention Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Arcus Biosciences | Cancer Prevention Research Institute of Texas"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Genentech"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Once Upon a Time Foundation | Telix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga PSMA-11","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Once Upon a Time Foundation | Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Once Upon a Time Foundation | Telix Pharmaceuticals"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Genentech"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"scPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ scPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ scPharmaceuticals"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ CareDx","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ CareDx"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ GSK"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Akeso | Josephine Hughes Sterling Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ligufalimab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Akeso | Josephine Hughes Sterling Foundation","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Akeso | Josephine Hughes Sterling Foundation"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Elpida Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Melpida Gene Therapy","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ UT Southwestern Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ UT Southwestern Medical Center"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Expanded Collaboration","leadProduct":"TSHA-112","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Taysha Gene Therapies","highestDevelopmentStatusID":"2","companyTruncated":"UT Southwestern Medical Center \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Exelixis"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"UT Southwestern Medical Center \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by UT Southwestern Medical Center

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Ligufalimab

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Akeso | Josephine Hughes Sterling Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Ligufalimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          January 23, 2025

                          Lead Product(s) : Ligufalimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Akeso | Josephine Hughes Sterling Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Iomab-B is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : Iomab-B

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Actinium pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Enfortumab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Bladder Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 01, 2024

                          Lead Product(s) : Enfortumab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Astellas Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          February 20, 2024

                          Lead Product(s) : Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Rocuronium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 26, 2024

                          Lead Product(s) : Rocuronium Bromide

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ketorolac is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pain, Postoperative.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 06, 2023

                          Lead Product(s) : Ketorolac Trometamol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Assertio Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : 68-Ga PSMA-11

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : Once Upon a Time Foundation | Telix Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : 68-Ga PSMA-11 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          September 21, 2023

                          Lead Product(s) : 68-Ga PSMA-11

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Once Upon a Time Foundation | Telix Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : All-Trans Retinoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 21, 2023

                          Lead Product(s) : Tretinoin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Cabozantinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 05, 2023

                          Lead Product(s) : Cabozantinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Exelixis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Two new gene therapy trials at UT Southwestern and Children’s Health funded through the consortium will test treatments for multiple sulfatase deficiency and Charcot-Marie-Tooth disease type 4J (CMT4J). Each clinical trial will include between eight an...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 27, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank